[Federal Register Volume 67, Number 86 (Friday, May 3, 2002)]
[Notices]
[Page 22414]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-11072]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army


Availability for Non-Exclusive, Exclusive, or Partially Exclusive 
Licensing of U.S. Patent Application Concerning a Method of Making a 
Vaccine for Anthrax

AGENCY: Department of the Army, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with 37 CFR 404.6 and 404.7, announcement is 
made of the availability for licensing of U.S. Patent Application 
Serial No. 09/520,215 entitled ``Method of Making a Vaccine for 
Anthrax,'' filed March 7, 2000. The United States Government, as 
represented by the Secretary of the Army has rights in this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, 
Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth 
Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul 
Mele, Office of Research & Technology Assessment, (301) 619-6664, both 
at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: A method of making a vaccine from a 
protective antigen. The protective antigen is useful against Bacillus 
anthracis. The protective antigen is produced by an asporogenic 
organism, which overproduces the desired antigen. The asporogenic 
organism is a recombinant asporogenic B. anthracis. The recombinant 
asporogenic B. anthracis was derived from a  Sterne-1(pPA102) 
strain of bacteria and binds to dye when grown on Congo Red Agar.

Luz D. Ortiz,
Army Federal Register Liaison Officer.
[FR Doc. 02-11072 Filed 5-2-02; 8:45 am]
BILLING CODE 3710-08-M